Vitamin D: metamorphosis from nutrient to hormonal system

By S. W. STANBURY, Department of Medicine, University of Manchester, The Royal Infirmary, Manchester

In so far as a vitamin is regarded as an essential nutrient, 'vitamin D' cannot be assigned that function, although it can acquire the role when social and economic factors pervert the normal physiological means of its provision. The natural vitamin, cholecalciferol (vitamin D₃), is biologically inert and must undergo successive enzymatic hydroxylations, at C-25 in the liver and at C-1 in the kidney, to produce the effector molecule, 1,25-dihydroxycholecalciferol (1,25-(OH)₂D₃; Fraser, 1980). Ergocalciferol (vitamin D₂), which is obtained exclusively from the diet, is similarly converted to its 1,25-dihydroxy derivative; it is probably as active as cholecalciferol in man but not in all animal species. The physiological source of 'vitamin D' is the cholecalciferol produced photochemically in the epidermis from the pro-vitamin, 7-dehydrocholesterol (Holick et al. 1977). The term calciferol is used to refer to either cholecalciferol or ergocalciferol and, when referring to the mixed metabolites of these two forms in plasma, the abbreviations 25-(OH)D and 1,25-(OH)₂D are used. The abbreviations 25-(OH)D₃ and 1,25-(OH)₂D₃ imply a known derivation from cholecalciferol. Although most vertebrates can probably absorb and utilize orally administered calciferols, the sun is the principal source of 'vitamin D' in man, even in northern climes and in countries practicing the fortification of foodstuffs (Haddad & Hahn, 1973; Preece et al. 1975; Poskitt et al. 1979). The foetus and the neonate, unexposed to ultraviolet irradiation, are dependent on maternal supply. Breast milk contains a water-soluble, sulphate ester of cholecalciferol (Sahashi et al. 1969) and there is indirect evidence that this material is absorbed and utilized by the suckling (Le Boulch et al. 1979; Noff & Edelstein, 1978). It is present in high concentration in human milk, especially in the early days of lactation (Lakdawala & Widdowson, 1977), and its excretion by this route may constitute a significant drain on maternal resources. The foetus receives cholecalciferol and 25-hydroxycholecalciferol (25-(OH)D₃) by placental transfer (Haddad et al. 1971; Hillman & Haddad, 1974). There is little transfer of 1,25-(OH)₂D₃ from mother to foetus in the rat (Noff & Edelstein, 1978), and in the human baby the concentration of 1,25-(OH)₂D in the placental venous blood is significantly lower than in the maternal blood (Steichen et al. 1980) but ovine placenta is reported as freely permeable to 1,25-(OH)₂D₃ (Ross et al. 1979).

Although it has long been known that cholecalciferol is produced in the epidermis by the action of u.v. irradiation on 7-dehydrocholesterol, it has only recently been proved that, as in vitro, the photochemical reaction is restricted to the production of pre-cholecalciferol (Holick et al. 1977). The subsequent slow isomerization of pre-cholecalciferol to cholecalciferol is temperature dependent, the equilibrium being about 80% in favour of cholecalciferol at 37°C and less at lower temperatures. This thermal equilibrium might alone affect the availability of...
cholecalciferol to cold-blooded animals at low environmental temperatures, but
there is grafted onto it a biological factor that may have more general relevance.
Cholecalciferol, as well as its principal metabolites, is carried in the blood in
association with a specific 'vitamin D binding' α-globulin (DBP); the affinity of
cholecalciferol for DBP is at least $10^3$ times greater than of pre-cholecalciferol
(Holick et al. 1979). Thus the selective binding of cholecalciferol to DBP and its
removal into the circulation would disturb the pre-cholecalciferol–cholecalciferol
equilibrium prevailing in skin at any particular temperature and determine the
slowly progressive utilization of the initial product of u.v. irradiation. In this sense
both molecules could be regarded as an epidermal store of 'vitamin D', available for
days or perhaps weeks after cessation of irradiation.

Vitamin D in man

In man, we have shown that the fractional conversion of cholecalciferol to $25$-(OH)$D_3$ is most efficient when the circulating concentration of the former is low
(Mawer, 1980) and have suggested that cholecalciferol entering the blood slowly
from the skin may be cleared quantitatively by $25$-hydroxylation in the liver
(Stanbury et al. 1980). Compatible with this proposal, a subcutaneous or
intramuscular depot of radioisotopically labelled cholecalciferol can produce a
slowly progressive increase in radioactive plasma $25$-(OH)$D_3$ to reach a
concentration about twenty-five times that of its precursor, radioactive plasma
cholecalciferol (Davies & Mawer, 1979). There are, as yet, few available
measurements of plasma calciferol in man; in Canadian adults in winter, a mean
total plasma calciferol of 2.2 μg/l (5.7 nmol/l) was associated with a mean total
have estimated the cutaneous production of cholecalciferol following a total of
15 min u.v. irradiation of restricted areas of human skin over a period of 17 d. On
the basis of the measured increment of plasma $25$-(OH)$D$ in the subjects irradiated,
they calculate an epidermal production of cholecalciferol of 0.024 nmol/cm². It is
evident, however, that prolonged irradiation of the whole body can cause a
significant increase of circulating cholecalciferol (Davie & Lawson, 1980) and
plasma concentrations as high as 12–52 μg/l (31–135 nmol/l) have been recorded
after 3–5 weeks treatment by u.v. irradiation of patients with psoriasis (Bjorkhem
et al. 1979). The subsequent fate of such circulating cholecalciferol after cessation
of irradiation is unknown but, judging from studies of injected radioactive
cholecalciferol, it is to be expected that it will disappear rapidly from the blood
(Mawer et al. 1971) by partition into fat and binding to tissue proteins (Mawer
et al. 1972).

Under ordinary conditions of living, when most of the body is clothed and solar
exposure is episodic, the principal molecular form of 'vitamin D' in blood is not
cholecalciferol but $25$-(OH)$D_3$ bound to DBP. The binding protein is present in
great excess and the plasma concentration of free $25$-(OH)$D_3$ is negligible (Bouillon
& Van Baelen, 1979). This and its prolonged survival in the blood (half-life
12–30 d; Mawer et al. 1971) makes $25$-(OH)$D_3$ an ideal, and probably inert,
storage form of the vitamin. DBP also penetrates into most nucleated cells, where it associates with a cytosol protein (Haddad & Walgate, 1976); since the volume of distribution of \(25-(OH)D_3\) is far greater than the volume of the plasma (Mawer et al. 1972; Gray et al. 1974), it is reasonable to infer that there is free exchange between extracellular and intracellular pools of bound \(25-(OH)D_3\). Although there is speculation that the intracellular \(25-(OH)D_3\) may subserve some specific function(s), this is unproved and it is probably simplest to regard it as part of the bodily store of 'vitamin D', of which the plasma \(25-(OH)D\) is the most easily measured index.

When cholecalciferol enters the blood rapidly, as after its intravenous injection (Mawer, 1980) but also after a single oral dose (Thompson et al. 1966), its concentration in plasma increases greatly. In both circumstances, about 80% of the absorbed dose is lost from the blood by uptake into tissues (Mawer et al. 1972; Krawitt et al. 1977) and there is a rapid increase of plasma \(25-(OH)D_3\) which reaches its maximum concentration within 1–3 d. This contrasts with events seen with a slow delivery of cholecalciferol into the blood, when utilization of cholecalciferol appears to be effectively complete and the resulting increase of plasma \(25-(OH)D_3\) reaches its maximum after a matter of weeks (Davies & Mawer, 1979). Oral pulse dosage with calciferol will thus result in an unphysiological, iatrogenic or factitious storage pool in the tissues, especially fat. This mechanism may serve to limit the potential toxic effects of high therapeutic oral dosage but it cannot be assumed that the tissue depot is readily available. It is possible to cure the clinical effects of vitamin D deficiency in the British immigrant Asian population with daily single doses of 450 IU (11.25 \(\mu\)g) or even 200 IU (5 \(\mu\)g) of calciferol (Stanbury et al. 1975, 1981); this suggests that no more than 1 \(\mu\)g/d retained in the metabolic pool may be adequate to correct the deficiency. Yet, on withdrawing such therapy, biochemical relapse within weeks is a commonplace. Thus the cumulative 'store', resulting from sequestration in the tissues of 80% of each daily dose, appears to be of limited availability to the circulation when treatment is stopped. There is, however, some indirect evidence that the calciferol in fat may become available when fat is mobilized in the course of weight reduction (Connors et al. 1976). It must be emphasized that these remarks on the disposition of an oral dose refer to pulse dosage such as is used therapeutically. It is conceivable that calciferol ingested as a constituent of food is absorbed more slowly, with a lesser rise in its plasma concentration and its consequential more complete utilization. No observations are available on the metabolism of calciferol ingested as food.

**Vitamin D requirements**

Orally administered calciferol, perhaps even in a daily dose as low as 2.5 \(\mu\)g (100 IU), can provide the bodily requirement; but this means of provision is effective only so long as oral intake is continued, and dosage of this magnitude produces barely detectable increases of plasma \(25-(OH)D\). Casual solar exposure of uncovered areas of skin during the summer months may increase the mean
concentration of plasma 25-(OH)D by 10 pg/l (25 nmol/l) or more above the winter mean; the concentration in the individual in winter is determined by the level attained in summer (Lawson et al. 1979). In individuals receiving any exposure to effective sunshine, the diet makes a negligible contribution to the total 25-(OH)D in plasma. Despite this, even in subjects with low estimated dietary vitamin D (0.8–2.3 µg/d), a significant correlation has been found between plasma 25-(OH)D and intake (Hunt et al. 1976). The plasma 25-(OH)D increases progressively as the daily oral intake is increased from micrograms to milligrams and, at the latter level of dosage, concentrations as high as 500–800 pg/l (1.25–2 mmol/l) can be attained. Throughout that range of dosage, the relationship between daily intake and plasma 25-(OH)D is best described by a power function (Stamp et al. 1977). Similarly, following increasing intravenous doses of cholecalciferol, the resulting increment of plasma 25-(OH)D$_3$ is a power function of the induced increase of plasma cholecalciferol (Mawer, 1980; Stanbury et al. 1980). Such observations and collateral studies of the control of 25-(OH)D production by the isolated perfused liver (Mawer & Reeve, 1977) have led to the suggestion that the presence of significant concentrations of cholecalciferol in the circulation or in the liver exerts a constraint on quantitative 25-hydroxylation (Stanbury et al. 1980). When high oral dosage is continued, this constraint is inadequate to prevent the development of concentrations of plasma 25-(OH)D that can be directly toxic, probably because the concentration of unbound 25-(OH)D increases rapidly when the total plasma concentration exceeds 100 µg/l (250 nmol/l) (Bouillon & Van Baelen, 1979). It is consequently of particular importance that, after months of whole body exposure to summer sunshine, the plasma 25-(OH)D in man appears not to exceed a maximum concentration of about 80 µg/l (200 nmol/l) (Haddad & Chyu, 1971). This can only imply that the delivery of cholecalciferol from skin to liver is limited and, as yet, the mechanism of this limitation is a matter of speculation (Davie & Lawson, 1980; Stanbury et al. 1980). Effectively, the epidermis functions as an endocrine organ that utilizes the energy of u.v. light to produce its secretion, cholecalciferol; and that integrates with the liver to produce a circulating storage form or pro-hormone (25-(OH)D$_3$), of prolonged half-life, in quantities that avoid the causation of intoxication from solar exposure.

**Biological activity of vitamin D in health and disease**

Although the point is debated, it is probable that 25-(OH)D$_3$ is inert biologically at physiological concentrations. Its primary function is to act as precursor for the renal production of the hormonal form, 1,25-(OH)$_2$D$_3$. This highly potent renal metabolite is active in picomolar concentrations and it is the effector molecule responsible for the expression of most, if not all, the biological effects of the ‘vitamin’. In healthy, ‘vitamin D’ replete individuals its concentration in plasma is maintained within relatively narrow limits (33 ng/l, SD 6, or approximately 100 pmol/l; Haussler et al. 1976) at a level about 1/500 that of plasma 25-(OH)D but largely independently of the latter. Ostensibly, therefore, measurement of plasma
25-(OH)D should provide an index of the bodily reserve of pro-hormone, and measurement of plasma 1,25-(OH)$_2$D an index of prevailing biological action. Generally this is true but the production of 1,25-(OH)$_2$D$_3$ varies with contemporary needs; its renal synthesis is regulated, principally by the parathyroid glands, in response to a primary change of plasma calcium (Fraser, 1980). The plasma 1,25-(OH)$_2$D is elevated above the 'normal range' in response to the requirements of mammalian pregnancy and lactation (Kumar et al. 1979; Boass et al. 1977) of avian egg production (Kenney, 1976) and when the intake of Ca is reduced; conversely, it is reduced if the plasma Ca is raised or the dietary intake of Ca is abnormally high (Adams et al. 1979). There is also evidence that the activity of the renal 25-hydroxycholecalciferol-1a-hydroxylase may be influenced, directly or indirectly, by prolactin (Spanos et al. 1976), growth hormone (Spanos et al. 1978), oestrogens (Kenney, 1976), adrenal glucocorticoids (Lukert et al. 1976) and probably also by placental lactogen and insulin. Consequently, even in health, the level of plasma 1,25-(OH)$_2$D can be interpreted only in terms of the plane of mineral nutrition and the prevailing physiological state, from the neonatal period, through growth to maturity, pregnancy, lactation etc.

In disease, interpretation may be complicated by structural or functional abnormalities in the kidneys or parathyroid glands, or by reduced sensitivity of its target tissues to 1,25-(OH)$_2$D$_3$. The plasma 1,25-(OH)$_2$D may be low, in association with normal or elevated plasma 25-(OH)D, in destructive renal disease, in renal intoxication with lead (Rosen et al. 1980) or cadmium (personal observations), or with a genetically determined defect of renal 25-hydroxycholecalciferol-1a-hydroxylase activity ('vitamin D dependency' (type 1); Scriver et al. 1978). In an exceptionally rare disease ('vitamin D dependency' (type 2); Marx et al. 1978) active rickets is associated with greatly increased concentrations of plasma 1,25-(OH)$_2$D and reduced tissue response to its actions. In privational, 'vitamin D-deficiency' rickets or osteomalacia, plasma concentrations of both 25-(OH)D and 1,25-(OH)$_2$D may be appropriately low or unmeasurable; but small oral doses of calciferol can produce a rapid increase of plasma 1,25-(OH)$_2$D to supranormal levels without necessarily inducing a significant increase of plasma 25-(OH)D (Stanbury et al. 1981). Consequently, in a patient with the clinical features of privational rickets or osteomalacia, the plasma 1,25-(OH)$_2$D can be low, normal or very high.

The assay for plasma 25-(OH)D in general use does not discriminate between 25-(OH)D$_3$ and 25-(OH)D$_2$ and it provides an integrated measure of reserves acquired from endogenous and exogenous sources. It has proved invaluable in studies of populations in which solar exposure and dietary intake are both marginal or inadequate, and in which there is a significant incidence of osteomalacia. Such populations at risk include the indigenous elderly, both those living at home (Lawson et al. 1979) and especially patients in long-stay geriatric hospitals (Corless et al. 1975), and the children and adult women of the immigrant Asian population (Holmes et al. 1973; Preece et al. 1973). In these individuals, the diet may provide no more than 1 µg calciferol/d; the hospitalized patients may get no
exposure to u.v. light and this is limited in the Asian by social customs. In both
groups, the mean plasma 25-(OH)D and its seasonal variation are less than in the
general population and concentrations less than 4 μg/l (10 nmol/l) are common.
This is in the range of concentrations at which rickets and osteomalacia are
encountered clinically, but the presence of active bone disease cannot be equated
with any absolute concentration of plasma 25-(OH)D. It is an unresolved question
as to how, when and why particular individuals among a deprived population
develop complicating bone disease. It is believed by some workers that the
alternative metabolites of 25-(OH)D$_3$, 24,25-dihydroxycholecalciferol (Ornay et al.
1978) and 25,26-dihydroxycholecalciferol (Miravet et al. 1976) or even 25-(OH)D$_3$
itself, play an essential role in the mineralization of bone. If this were the case, the
plasma 25-(OH)D should provide a predictable index of the development of bone
disease, since the formation of both these dihydroxylated metabolites is a direct
function of the prevailing concentration of plasma 25-(OH)D (Taylor et al. 1976;
Stanbury & Mawer, 1980). In man, the present evidence suggests that no
molecular form other than 1,25-(OH)$_2$D is required for the mineralization of bone
(Stanbury et al. 1981). The collateral problem of prophylaxis in populations at risk
has a hypothetically simple solution; all it requires is that the individual receives an
exposure to summer sunshine no greater than is received by the average active
member of the community. In default of the passive therapy of gardening or a daily
walk in the sun, exposure to artificial sources of u.v. irradiation has proved
effective in geriatric patients in hospital (Corless et al. 1978). In most of those at
risk, it may be necessary to resort to the fortification of food or the provision of an
oral supplement: even the old-fashioned ‘stosstherapie’, given as an intramuscular
dose of 2.5 mg ergocalciferol, increases plasma 25-(OH)D in a manner closely
resembling that produced by irradiation and maintains its concentration at
satisfactory levels for 3 months or more (Davies & Mawer, 1979).

Cited Departmental researches were supported by a Programme Grant from the
Medical Research Council.

REFERENCES
Bjorkhem, I., Holmbeg, I., Kristiansen, R., Larsson, A. & Pedersen, J. I. (1979). In Vitamin D:
267, 630.
Bouillon, R. & Van Baelen, H. (1979). In Vitamin D: Basic Research and its Clinical Application,
p. 137 [A. W. Norman, editor]. Berlin: de Gruyter.
Corless, D., Gupta, S. P., Switala, S., Barragry, J. M., Boucher, B. J., Cohen, R. D. & Diffey, B. L.
Davies, M. & Mawer, E. B. (1979). In Vitamin D: Basic Research and its Clinical Application,
p. 609 [A. W. Norman, editor]. Berlin: de Gruyter.
Symposium Proceedings 1981


